Drug intelligence / Profile preview

PEGASEMP

Development stage: Preclinical
Lead developer: TREAT U
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

PEGASEMP is a proprietary dual-targeted pegylated nanoparticle platform developed by TREAT U for the delivery of small molecule cytostatic drugs. The platform is designed to target both tumor cells and angiogenic blood vessel endothelial cells within the tumor microenvironment, aiming to improve the therapeutic index of chemotherapy. Doxorubicin has been utilized as a proof-of-concept payload for the platform. PEGASEMP is currently in preclinical development for several oncology indications, including breast cancer, lung cancer, prostate cancer, melanoma, leukemia, and malignant mesothelioma.

Brand names: PEGASEMP
Other names: PEGASEMPPEGASEMP-TREAT U

Targets

DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on PEGASEMP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEGASEMP.

Explore the full profile